Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection

被引：6

作者：

Taguchi, Hiroki ^{[1
,2
]}

Otsuka, Taiga ^{[3
,4
]}

Shimokawa, Mototsugu ^{[5
,6
]}

Arima, Shiho ^{[7
,8
]}

Hashimoto, Shinichi ^{[7
,8
]}

Ido, Akio ^{[7
,8
]}

Koga, Futa ^{[9
]}

Ueda, Yujiro ^{[10
]}

Nakazawa, Junichi ^{[11
]}

Komori, Azusa ^{[12
]}

Otsu, Satoshi ^{[12
]}

Fukahori, Masaru ^{[13
]}

Makiyama, Akitaka ^{[14
,15
]}

Honda, Takuya ^{[16
]}

Shibuki, Taro ^{[17
,18
]}

Mizuta, Toshihiko ^{[17
,19
]}

Mitsugi, Kenji ^{[20
]}

Nio, Kenta ^{[21
]}

Ide, Yasushi ^{[22
]}

Ureshino, Norio ^{[3
,23
]}

Shirakawa, Tsuyoshi ^{[24
,25
]}

机构：

[1] Saiseikai Sendai Hosp, Dept Gastroenterol, Kagoshima, Japan

[2] Izumi Gen Med Ctr, Dept Gastroenterol, Kagoshima, Japan

[3] Saga Med Ctr Koseikan, Dept Med Oncol, Saga, Japan

[4] Minato Med Clin, Dept Internal Med, Chuo Ku, 3-11-3 Nagahama, Fukuoka 8100072, Japan

[5] Natl Hosp Org, Clin Res Inst, Kyushu Canc Ctr, Fukuoka, Japan

[6] Yamaguchi Univ, Grad Sch Med, Dept Biostat, Yamaguchi, Japan

[7] Kagoshima Univ, Grad Sch Med & Dent Sci, Digest & Lifestyle Dis, Kagoshima, Japan

[8] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan

[9] Saga Med Ctr Koseikan, Dept Hepatobiliary & Pancreatol, Saga, Japan

[10] Japanese Red Cross Kumamoto Hosp, Dept Hematol & Oncol, Kumamoto, Japan

[11] Kagoshima City Hosp, Dept Med Oncol, Kagoshima, Japan

[12] Oita Univ, Fac Med, Dept Med Oncol & Hematol, Oita, Japan

[13] Kurume Univ Hosp, Div Gastroenterol, Dept Internal Med, Kurume, Fukuoka, Japan

[14] Japan Community Healthcare Org, Depat Hematol Oncol, Kyushu Hosp, Fukuoka, Japan

[15] Gifu Univ Hosp, Canc Ctr, Gifu, Japan

[16] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, Nagasaki, Japan

[17] Imari Arita Kyoritsu Hosp, Dept Internal Med, Saga, Japan

[18] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan

[19] Fujikawa Hosp, Dept Internal Med, Saga, Japan

[20] Hamanomachi Hosp, Dept Med Oncol, Fukuoka, Japan

[21] Sasebo Kyosai Hosp, Dept Med Oncol, Nagasaki, Japan

[22] Karatsu Red Cross Hosp, Dept Internal Med, Saga, Japan

[23] Kimitsu Chuo Hosp, Dept Med Oncol, Chiba, Japan

[24] Fukuoka Wajiro Hosp, Dept Med Oncol, Fukuoka, Japan

[25] Karatsu Higashi Matsuura Med Assoc Ctr, Saga, Japan

来源：

ANTICANCER RESEARCH | 2021年 / 41卷 / 07期

关键词：

FOLFIRINOX (FFX); gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP); recurrent pancreatic cancer after resection; ADJUVANT CHEMOTHERAPY; OPEN-LABEL; THERAPY; PHASE-3; SOCIETY; TRIAL;

D O I：

10.21873/anticanres.15145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The aim of the study was to evaluate gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP) and FOLFIRINOX for recurrent pancreatic cancer (rPC) after resection. Patients and Methods: Forty-four patients with rPC and 211 with de novo metastatic pancreatic cancer (mPC) who received GnP or FOLFIRINOX as first-line chemotherapy were retrospectively analyzed. Results: On crude analysis, the median overall survival (OS) was significantly longer in the rPC group than in the mPC group (14.0 vs. 10.6 months, respectively; p=0.02). However, the difference was not significant on adjusted analysis using the Cox proportional hazards model (adjusted p=0.90). Patients receiving FOLFIRINOX (n=10) and GnP (n=34) in the rPC group had comparable OS (medians, 12.2 vs. 14.4 months, respectively; p=0.82) even after adjusting for covariates using the Cox model (adjusted p=0.18). Conclusion: The outcomes of patients in the rPC and mPC groups were comparable following chemotherapy. Both FOLFIRINOX and GnP may be reasonable options for treating rPC.

引用

页码：3573 / 3582

页数：10

共 50 条

[1] Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer
Saltz, Leonard B.
Bach, Peter B.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (05): : 478 - 478
[2] Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer REPLY
Von Hoff, Daniel D.
Goldstein, David
Renschler, Markus F.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (05): : 479 - 480
[3] Albumin-bound paclitaxel plus gemcitabine after first-hue FOLFIRINOX therapy in patients with pancreatic cancer.
Salem, Mohamed E.
Alistar, Angela Tatiana
Dyson, Gregory
Stanski, Natalja
Mahaseth, Hemchandra
Chol, Minsig
Shields, Anthony Frank
Philip, Agop Philip
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel for Patients with Inoperable Pancreatic Cancer: Experience at a Single Oncology Centre
Lee, T. Y.
Lam, M. H. C.
Cheung, K. M.
Cheng, H. C.
Ngan, R. K. C.
Wong, K. H.
HONG KONG JOURNAL OF RADIOLOGY, 2020, 23 (01): : 27 - 33
[5] BUDGET IMPACT OF ALBUMIN-BOUND PACLITAXEL plus GEMCITABINE IN THE TREATMENT OF METASTATIC PANCREATIC CANCER
Binder, G.
Whiting, S.
Milentijevic, D.
Penenberg, D.
Wei, X.
Kayitalire, L.
Renschler, M. F.
VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
[6] Combined Therapy With Gemcitabine Hydrochloride and Nanoparticle Albumin-bound Paclitaxel Enabled Resection in a Patient With Unresectable Locally Advanced Pancreatic Cancer
Sakaue, Takahiko
Fukahori, Masaru
Miwa, Keisuke
Ushijima, Tomoyuki
Yasumoto, Makiko
Kuraoka, Kei
Ishida, Yuusuke
Nagasu, Sachiko
Ishikawa, Hiroto
Mihara, Yuutarou
Nakayama, Masamichi
Naitou, Yoshiki
Okabe, Yoshinobu
Torimura, Takuji
PANCREAS, 2019, 48 (06) : 859 - 859
[7] Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.
Sharif, Shahriar
Zureikat, Amer H.
Novelli, Paula M.
Lopez, Charles D.
Kardosh, Adel
Chung, Ki Y.
Jones, Wesley B.
Hatoum, Hassan
Meredith, Kenneth Lee
Zervos, Emmanuel E.
Ucar, Antonio
Gandhi, Ripal T.
Nazemzadeh, Reza
Kasi, Pashtoon Murtaza
Vandestraeten, Erik
Decaestecker, Jochen
Delaunoit, Thierry
Li, Charles Charles
Agah, Ramtin
Pishvaian, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[8] Nanoparticle albumin-bound paclitaxel for metastatic breast cancer
Harries, M
Ellis, P
Harper, P
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 7768 - 7771
[9] Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review
Kase, Adam M.
Azzouqa, Abdel-Ghani
Kochuveettil, Swapna
Colon-Otero, Gerardo
CANCER MEDICINE, 2023, 12 (08): : 9434 - 9438
[10] Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
Takahashi, Akiko
Noro, Rintaro
Takano, Natsuki
Hisakane, Kakeru
Takahashi, Satoshi
Fukuizumi, Aya
Omori, Miwako
Sugano, Teppei
Takeuchi, Susumu
Nakamichi, Shinji
Miyanaga, Akihiko
Minegishi, Yuji
Kubota, Kaoru
Seike, Masahiro
Gemma, Akihiko
MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (04)

← 1 2 3 4 5 →